Bio-Rad launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for cell and gene therapy production
Validated detection of viral replication genes using Droplet Digital™ PCR during cell and gene therapy production
4 Mar 2024
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has launched the Vericheck ddPCR™ Replication Competent Lentivirus Kit and the Vericheck ddPCR™ Replication Competent AAV Kit. The kits provide rapid, cost-effective solutions for the absolute quantification of replication competent lentivirus (RCL) and replication competent adeno-associated virus (RCAAV), supporting the safe and effective production of cell and gene therapies.
Replication competent viruses (RCVs) can infect cells and replicate to produce additional virions. RCVs can be generated through recombination events between the transfer plasmid and either the production plasmids or the packaging cell line's genome. Fundamental to the safety of emerging cell and gene therapies, RCV testing of samples must be performed throughout the production process.
Bio-Rad’s Vericheck ddPCR kits for detection of RCL and RCAAV provide a validated solution for highly specific and highly sensitive detection and quantification of viral replication genes, potentially indicating an RCV. The tests are designed for Bio-Rad's QX Droplet Digital™ PCR (ddPCR™) platforms, with a simple workflow including automated data analysis and flexible sample throughput. Compared to traditional cell culture–based methods for RCV testing, the kits significantly reduce cost and turnaround time, achieving results in as little as eight hours.
